QuidelOrtho Amends Credit Agreement, Resets Leverage and Interest Coverage Covenants Through 2029
QDEL is trading near its 52-week low of $9.92 (4.2% above the low).
Summary
QuidelOrtho amended its credit agreement to relax financial covenants through 2029, providing near-term relief but adding new restrictions and a consent fee.
Key Events · Financing and Capital Events · QDEL
-
Covenant Relief Period Established
Amendment No. 1 resets financial covenants through September 30, 2029, with maximum leverage ratio of 5.50x through July 2, 2028, stepping down to 4.25x by September 30, 2029.
-
Interest Coverage Requirement Reduced
Minimum consolidated interest coverage ratio lowered to 2.25x through July 2, 2028, rising to 3.00x by September 30, 2029.
-
New Restrictions During Relief Period
Lenders imposed a $250 million Pro Forma Cash Cap, limits on incremental debt, investments, restricted payments, and dispositions, plus a 0.125% consent fee on Revolving Credit Commitments and Term A Loans.
-
Follows Guidance Cut and Negative Cash Flow
This amendment comes after Q2 2026 results slashed full-year guidance and showed negative operating cash flow, indicating balance-sheet strain.
Analysis · QDEL · Life Sciences
QuidelOrtho has secured covenant relief from its lenders, resetting its maximum leverage ratio to 5.50x and minimum interest coverage to 2.25x through mid-2028. This follows a Q2 2026 report that slashed full-year guidance and showed negative operating cash flow. The amendment buys breathing room on its $3.4 billion credit facility, but the new restrictions — a $250 million cash cap, limits on investments and restricted payments, and a consent fee — show lenders are tightening their grip. The stock trades near its 52-week low, and this filing confirms the company is managing a strained balance sheet rather than growing out of it.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QDEL was trading at $10.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $709.1M. The 52-week trading range was $9.92 to $35.58. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.